Ecubectedin (PM54)
Advanced Solid Tumors
Key Facts
About PharmaMar
Founded in 1986, PharmaMar's mission is to harness marine biodiversity to create life-changing oncology therapies. Its key achievement is the development and global commercialization of Yondelis® (trabectedin), a first-in-class drug for soft tissue sarcoma and ovarian cancer, which provides a revenue foundation. The company's strategy leverages its proprietary marine discovery platform to build a sustainable pipeline of novel small molecules, focusing on areas of high unmet need in oncology. PharmaMar operates as a fully integrated entity, controlling the entire process from research to sales.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |
| BP1001-A | Bio-Path Holdings | Phase 1 |